At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 179 enrolled
Drug / intervention
Tropisetron +2 moredrug
Likely dose
Tropisetron 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Tropisetron With Risperidone for Schizophrenia
In Brief
A Phase 3 clinical trial evaluating Tropisetron, Placebo, and 1 other intervention for Smoking Cessation and Schizophrenia. Completed, enrolled 179 participants across 2 sites in 2 countries.
Detailed Summary
This study will determine the effectiveness of tropisetron plus risperidone in improving cognitive symptoms in Chinese people with schizophrenia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoking Cessation, Schizophrenia
CountriesChina, United States
CollaboratorsNational Institute of Mental Health (NIMH)
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2006
First PostedFeb 2007
Primary CompletionFeb 2011
Study CompletionAug 2011
TodayJul 2026
First PostedFeb 14, 2007
Enrollment StartNov 1, 2006
Primary CompletionFeb 1, 2011
Study CompletionAug 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 19.4 years ago
Interventions
Tropisetrondrug
10 mg/day
Placebodrug
placebo
Risperidonedrug
6mg/day